Related Experiment Video
Updated: May 14, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Once weekly exenatide: efficacy, tolerability and place in therapy
1Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Diabetes, Obesity & Metabolism
|February 22, 2013
Summary
Exenatide once weekly offers effective glucose lowering and weight loss for type 2 diabetes mellitus (T2DM) patients. This formulation provides sustained release, with fewer gastrointestinal side effects than other GLP-1 receptor agonists.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) management requires effective glucose-lowering agents.
- Current therapies include oral agents and injectable medications.
- The development of long-acting formulations aims to improve patient adherence and glycemic control.
Purpose of the Study:
- To evaluate the efficacy and tolerability of exenatide once weekly in patients with T2DM.
- To compare exenatide once weekly with other antidiabetic treatments, including basal insulin.
Main Methods:
- Randomized clinical trials were conducted.
- Exenatide once weekly was administered subcutaneously via dissolvable microspheres.
- Efficacy was assessed by glycaemic improvement and weight changes.
- Tolerability was monitored, focusing on gastrointestinal side effects.
Main Results:
- Exenatide once weekly demonstrated significant glycaemic improvement and moderate weight loss in T2DM patients.
- It proved more effective than titrated basal insulin in patients on metformin or metformin plus sulfonylurea.
- Gastrointestinal side effects (nausea, vomiting, diarrhea) were the most common, but occurred less frequently than with exenatide twice daily or liraglutide.
Conclusions:
- Exenatide once weekly is a valuable therapeutic option for T2DM.
- Its sustained-release formulation offers an effective treatment with a favorable tolerability profile compared to other GLP-1 receptor agonists.
- Further discussion is warranted regarding its optimal place in T2DM pharmacotherapy.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:30Electroconvulsive Therapy
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...